Waning immunity and microbial vaccines-workshop of the National Institute of Allergy and infectious diseases

Clinical and Vaccine Immunology

Volumn 24, Issue 7, 2017, Pages

  Gu, Xin Xing ^a   Plotkin, Stanley A ^b   Edwards, Kathryn M ^c   Sette, Alessandro ^d   Mills, Kingston H G ^e   Levy, Ofer ^f,g   Sant, Andrea J ^h   Mo, Annie ^a   Alexander, William ^a   Lu, Kristina T ^a   Taylor, Christopher E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^e TRINITY COLLEGE DUBLIN   (Ireland)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Adjuvants; Bordetella pertussis; Immunity; Influenza; Malaria; Mumps; Neisseria meningitidis; Salmonella; Vaccines

Indexed keywords

BACTERIAL VACCINE; INFLUENZA VACCINE; MALARIA VACCINE; MENINGOCOCCUS VACCINE; MUMPS VACCINE; PERTUSSIS VACCINE; SALMONELLA ENTERICA SEROVAR TYPHI VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; DRUG CARRIER; IMMUNOLOGICAL ADJUVANT;

ARTICLE; CLINICAL RESEARCH; HUMAN; IMMUNITY; INFLUENZA; MALARIA; MENINGOCOCCOSIS; MUMPS; NATIONAL HEALTH ORGANIZATION; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; SALMONELLA; SALMONELLOSIS; TRANSLATIONAL RESEARCH; TYPHOID FEVER; CELLULAR IMMUNITY; DRUG DELIVERY SYSTEM; EDUCATION; HUMORAL IMMUNITY; IMMUNOLOGY; ISOLATION AND PURIFICATION; TIME FACTOR; UNITED STATES;

ADJUVANTS, IMMUNOLOGIC; BACTERIAL VACCINES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EDUCATION; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MALARIA VACCINES; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (U.S.); TIME FACTORS; UNITED STATES; VIRAL VACCINES;

EID: 85021909503     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00034-17     Document Type: Article

References (89)

1. Landry S, Heilman C. 2005. Future directions in vaccines: the payoffs of basic research. Health Aff (Millwood) 24:758-769. https://doi.org/10.1377/hlthaff.24.3.758.
2. Roush SW, Murphy TV. 2007. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 298:2155-2163. https://doi.org/10.1001/jama.298.18.2155.
3. Nabel GJ. 2013. Designing tomorrow's vaccines. N Engl J Med 368:551-560. https://doi.org/10.1056/NEJMra1204186.
4. Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, Van-Wormer JJ. 2015. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine 33:246-251. https://doi.org/10.1016/j.vaccine.2014.06.052.
5. Schwartz KL, Kwong JC, Deeks SL, Campitelli MA, Jamieson FB, Marchand-Austin A, Stukel TA, Rosella L, Daneman N, Bolotin S, Drews SJ, Rilkoff H, Crowcroft NS. 2016. Effectiveness of pertussis vaccination and duration of immunity. CMAJ 188:E399-E406. https://doi.org/10.1503/cmaj.160193.
6. van Twillert I, Han WG, van Els CA. 2015. Waning and aging of cellular immunity to Bordetella pertussis. Pathog Dis 73: ftv071. https://doi.org/10.1093/femspd/ftv071.
7. Mooi FR, Van Der Maas NA, De Melker HE. 2014. Pertussis resurgence: waning immunity and pathogen adaptation. Two sides of the same coin. Epidemiol Infect 142:685-694. https://doi.org/10.1017/S0950268813000071.
8. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. 2012. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 367:1012-1019. https://doi.org/10.1056/NEJMoa1200850.
9. Cortese MM, Jordan HT, Curns AT, Quinlan PA, Ens KA, Denning PM, Dayan GH. 2008. Mumps vaccine performance among university students during a mumps outbreak. Clin Infect Dis 46:1172-1180. https://doi.org/10.1086/529141.
10. Vandermeulen C, Roelants M, Vermoere M, Roseeuw K, Goubau P, Hoppenbrouwers K. 2004. Outbreak of mumps in a vaccinated child population: a question of vaccine failure? Vaccine 22:2713-2716. https://doi.org/10.1016/j.vaccine.2004.02.001.
11. Plotkin SA. 2016. The importance of persistence. Clin Infect Dis 63:S117-S118. https://doi.org/10.1093/cid/ciw525.
12. Centers for Disease Control and Prevention. 2016. Pertussis cases by year (1922-2015). CDC, Atlanta, GA. https://www.cdc.gov/pertussis/surv-reporting/cases-by-year.html.
13. Mattoo S, Cherry JD. 2005. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 18:326-382. https://doi.org/10.1128/CMR.18.2.326-382.2005.
14. Klein NP. 2014. Licensed pertussis vaccines in the United States: history and current state. Hum Vaccin Immunother 10:2684-2690. https://doi.org/10.4161/hv. 29576.
15. Tartof SY, Lewis M, Kenyon C, White K, Osborn A, Liko J, Zell E, Martin S, Messonnier NE, Clark TA, Skoff TH. 2013. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 131:e1047-e1052. https://doi.org/10.1542/peds.2012-1928.
16. Schure RM, Hendrikx LH, de Rond LG, Öztürk K, Sanders EA, Berbers GA, Buisman AM. 2013. Differential T- and B-cell responses to pertussis in acellular vaccine-primed versus whole-cell vaccine-primed children 2 years after preschool acellular booster vaccination. Clin Vaccine Immunol 20:1388-1395. https://doi.org/10.1128/CVI.00270-13.
17. Ross PJ, Sutton CE, Higgins S, Allen AC, Walsh K, Lavelle EC, McLoughlin RM, Mills KH. 2013. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog 9:e1003264. https://doi.org/10.1371/journal.ppat.1003264.
18. Sheridan SL, Ware RS, Grimwood K, Lambert SB. 2012. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 308:454-456. https://doi.org/10.1001/jama.2012.6364.
19. Misiak A, Wilk MM, Raverdeau M, Mills KH. 2017. IL-17-producing innate and pathogen-specific tissue resident memory γδ T cells expand in the lungs of Bordetella pertussis-infected mice. J Immunol 198:363-374. https://doi.org/10.4049/jimmunol.1601024.
20. Dunne A, Mielke LA, Allen AC, Sutton CE, Higgs R, Cunningham CC, Higgins SC, Mills KH. 2015. A novel TLR2 agonist from Bordetella pertussis is a potent adjuvant that promotes protective immunity with an acellular pertussis vaccine. Mucosal Immunol 8:607-617. https://doi.org/10.1038/mi.2014.93.
21. Vaughan K, Seymour E, Peters B, Sette A. 2014. Substantial gaps in knowledge of Bordetella pertussis antibody and T cell epitopes relevant for natural immunity and vaccine efficacy. Hum Immunol 75:440-451. https://doi.org/10.1016/j.humimm.2014.02.013.
22. Bancroft T, Dillon MB, da Silva Antunes R, Paul S, Peters B, Crotty S, Lindestam Arlehamn CS, Sette A. 2016. Th1 versus Th2 T cell polarization by whole-cell and aceullular childhood pertussis vaccines persists upon re-immunization in adolescence and adulthood. Cell Immunol 304-305:35-43. https://doi.org/10.1016/j.cellimm.2016.05.002.
23. + T cells in blood. J Immunol 197:983-993. https://doi.org/10.4049/jimmunol.1600318.
24. Warfel JM, Beren J, Kelly VK, Lee G, Merkel TJ. 2012. Nonhuman primate model of pertussis. Infect Immun 80:1530-1536. https://doi.org/10.1128/IAI.06310-11.
25. Warfel JM, Zimmerman LI, Merkel TJ. 2014. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci USA 111:787-792. https://doi.org/10.1073/pnas.1314688110.
26. Morens DM, Taubenberger JK, Folkers GK, Fauci AS. 2010. Pandemic influenza's 500th anniversary. Clin Infect Dis 51:1442-1444. https://doi.org/10.1086/657429.
27. Barberis I, Myles P, Ault SK, Bragazzi NL, Martini M. 2016. History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines. J Prev Med Hyg 57:E115-E120.
28. Lambert LC, Fauci AS. 2010. Influenza vaccines for the future. N Engl J Med 363:2036-2344. https://doi.org/10.1056/NEJMra1002842.
29. Treanor JJ. 2016. Influenza vaccination. N Engl J Med 375:1261-1268. https://doi.org/10.1056/NEJMcp1512870.
30. Reber A, Katz J. 2013. Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines 12:519-536. https://doi.org/10.1586/erv. 13.35.
31. Díez-Domingo J, José-María B, Planelles-Catarino MV, Garcés-Sánchez M, Ubeda I, Jubert Rosich A, Marès J, Garcia-Corbeira P, Moris P, Teko M, Abeele CV, Gillardi P. 2015. Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination. Influenza Other Respir Viruses 9:68-77. https://doi.org/10.1111/irv. 12295.
32. Song JY, Cheong HJ, Hwang IS, Choi WS, Jo YM, Park DW, Cho GJ, Hwang TG, Kim WJ. 2010. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine 28:3929-3935. https://doi.org/10.1016/j.vaccine.2010.03.067.
33. Sarkander J, Hojyo S, Tokoyoda K. 2016. Vaccination to gain humoral immune memory. Clin Transl Immunol 5:e120. https://doi.org/10.1038/cti.2016.81.
34. Chiu C, Ellebedy AH, Wrammert J, Ahmed R. 2015. B cell responses to influenza infection and vaccination. Curr Top Microbiol Immunol 386:381-398. https://doi.org/10.1007/82-2014-425.
35. Alam S, Knowlden ZA, Sangster MY, Sant AJ. 2014. CD4 T cell help is limiting and selective during the primary B cell response to influenza virus infection. J Virol 88:314-324. https://doi.org/10.1128/JVI.02077-13.
36. + T-cell responses. J Infect Dis 211:1408-1417. https://doi.org/10.1093/infdis/jiu616.
37. Richards KA, Chaves FA, Alam S, Sant AJ. 2012. Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins. Vaccine 31:219-225. https://doi.org/10.1016/j.vaccine.2012.10.039.
38. + T-cell expansion predicts neutralizing antibody responses to monovalent, inactivated 2009 pandemic influenza A (H1N1) virus subtype H1N1 vaccine. J Infect Dis 207:297-305. https://doi.org/10.1093/infdis/jis684.
39. Nayak JL, Alam S, Sant AJ. 2013. Cutting edge: heterosubtypic influenza infection antagonizes elicitation of immunological reactivity to hemagglutinin. J Immunol 191:1001-1005. https://doi.org/10.4049/jimmunol.1203520.
40. DiPiazza A, Richards KA, Knowlden ZA, Nayak JL, Sant AJ. 2016. The role of CD4 T cell memory in generating protective immunity to novel and potentially pandemic strains of influenza. Front Immunol 7:10. https://doi.org/10.3389/fimmu.2016.00010.
41. Nachbagauer R, Krammer F. 2017. Universal influenza virus vaccines and therapeutic antibodies. Clin Microbiol Infect 23:222-228. https://doi.org/10.1016/j.cmi.2017.02.009.
42. WHO. 2016. World malaria report. WHO, Geneva, Switzerland. http://www.who.int/malaria/publications/world-malaria-report-2016/report/en/.
43. White MT, Verity R, Griffin JT, Asante KP, Owusu-Agyei S, Greenwood B, Drakeley C, Gesase S, Lusingu J, Ansong D, Adjei S, Agbenyega T, Ogutu B, Otieno L, Otieno W, Agnandji ST, Lell B, Kremsner P, Hoffman I, Martinson F, Kamthunzu P, Tinto H, Valea I, Sorgho H, Oneko M, Otieno K, Hamel MJ, Salim N, Mtoro A, Abdulla S, Aide P, Sacarlal J, Aponte JJ, Njuguna P, Marsh K, Bejon P, Riley EM, Ghani AC. 2015. Immunogenicity of the RTS, S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis 15:1450-1458. https://doi.org/10.1016/S1473-3099 (15) 00239-X.
44. Epstein JE, Paolino KM, Richie TL, Sedegah M, Singer A, Ruben AJ, Chakravarty S, Stafford A, Ruck RC, Eappen AG, Li T, Billingsley PF, Manoj A, Silva JC, Moser K, Nielsen R, Tosh D, Cicatelli S, Ganeshan H, Case J, Padilla D, Davidson S, Garver L, Saverino E, Murshedkar T, Gunasekera A, Twomey PS, Reyes S, Moon JE, James ER, Kc N, Li M, Abot E, Belmonte A, Hauns K, Belmonte M, Huang J, Vasquez C, Remich S, Carrington M, Abebe Y, Tillman A, Hickey B, Regules J, Villasante E, Sim BK, Hoffman SL. 2017. Protection against Plasmodium falciparum malaria by PfSPZ vaccine. JCI Insight 2:e89154. https://doi.org/10.1172/jci.insight.89154.
45. + T cell responses and protection against Plasmodium falciparum infection. PLoS One 8:e61395. https://doi.org/10.1371/journal.pone.0061395.
46. Taylor RR, Egan A, McGuinness D, Jepson A, Adair R, Drakely C, Riley E. 1996. Selective recognition of malaria antigens by human serum antibodies is not genetically determined but demonstrates some features of clonal imprinting. Int Immunol 8:905-915. https://doi.org/10.1093/intimm/8.6.905.
47. Akpogheneta OJ, Duah NO, Tetteh KK, Dunyo S, Lanar DE, Pinder M, Conway DJ. 2008. Duration of naturally acquired antibody responses to blood-stage Plasmodium falciparum is age dependent and antigen specific. Infect Immun 76:1748-1755. https://doi.org/10.1128/IAI.01333-07.
48. White MT, Griffin JT, Akpogheneta O, Conway DJ, Koram KA, Riley EM, Ghani AC. 2014. Dynamics of the antibody response to Plasmodium falciparum infection in African children. J Infect Dis 210:1115-1122. https://doi.org/10.1093/infdis/jiu219.
49. Wipasa J, Suphavilai C, Okell LC, Cook J, Corran PH, Thaikla K, Liewsaree W, Riley EM, Hafalla JC. 2010. Long-lived antibody and B cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog 6:e1000770. https://doi.org/10.1371/journal.ppat.1000770.
50. Teirlinck AC, McCall MB, Roestenberg M, Scholzen A, Woestenenk R, de Mast Q, van der Ven AJ, Hermsen CC, Luty AJ, Sauerwein RW. 2011. Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans. PLoS Pathog 7:e1002389. https://doi.org/10.1371/journal.ppat.1002389.
51. Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, Arens T, Beckers P, van Gemert G, van de Vegte-Bolmer M, van der Ven AJ, Luty AJ, Hermsen CC, Sauerwein RW. 2011. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 377:1770-1776. https://doi.org/10.1016/S0140-6736 (11) 60360-7.
52. Schats R, Bijker EM, van Gemert GJ, Graumans W, van de Vegte-Bolmer M, van Lieshout L, Haks MC, Hermsen CC, Scholzen A, Visser LG, Sauerwein RW. 2015. Heterologous protection against malaria after immunization with Plasmodium falciparum sporozoites. PLoS One 10:e0124243. https://doi.org/10.1371/journal.pone.0124243.
53. Bijker EM, Bastiaens GJ, Teirlinck AC, van Gemert GJ, Graumans W, van de Vegte-Bolmer M, Siebelink-Stoter R, Arens T, Teelen K, Nahrendorf W, Remarque EJ, Roeffen W, Jansens A, Zimmerman D, Vos M, van Schaijk BC, Wiersma J, van der Ven AJ, de Mast Q, van Lieshout L, Verweij JJ, Hermsen CC, Scholzen A, Sauerwein RW. 2013. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci USA 110:7862-7867. https://doi.org/10.1073/pnas.1220360110.
54. Ryg-Cornejo V, Ioannidis LJ, Ly A, Chiu CY, Tellier J, Hill DL, Preston SP, Pellegrini M, Yu D, Nutt SL, Kallies A, Hansen DS. 2016. Severe malaria infections impair germinal center responses by inhibiting T follicular helper cell differentiation. Cell Rep 14:68-81. https://doi.org/10.1016/j.celrep. 2015.12.006.
55. Buckle GC, Walker CL, Black RE. 2012. Typhoid fever and paratyphoid fever: systematic review to estimate global morbidity and mortality for 2010. J Glob Health 2:010401. https://doi.org/10.7189/jogh.01.010401.
56. Connerton P, Wain J, Hien TT, Ali T, Parry C, Chinh NT, Vinh H, Ho VA, Diep TS, Day NP, White NJ, Dougan G, Farrar JJ. 2000. Epidemic typhoid in Vietnam: molecular typing of multiple-antibiotic-resistant Salmonella enterica Serotype typhi from four outbreaks. J Clin Microbiol 38:895-897.
57. Rowe B, Ward LR, Threlfall EJ. 1997. Multidrug-resistant Salmonella typhi: a worldwide epidemic. Clin Infect Dis 1:S106-S109. https://doi.org/10.1093/clinids/24. Supplement-1. S106.
58. Szu SC. 2013. Development of Vi conjugate: a new generation of typhoid vaccine. Expert Rev Vaccines 12:1273-1286. https://doi.org/10.1586/14760584.2013.845529.
59. + T cells with predominant Vβ repertoires. Infect Immun 73:3521-3530. https://doi.org/10.1128/IAI.73.6.3521-3530.2005.
60. Sztein MB, Tanner MK, Polotsky Y, Orenstein JM, Levine MM. 1995. Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella typhi in humans. J Immunol 155:3987-3993.
61. Tacket CO, Pasetti MF, Sztein MB, Livio S, Levine MM. 2004. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. J Infect Dis 190:565-570. https://doi.org/10.1086/421469.
62. Wahid R, Salerno-Gonçalves R, Tacket CO, Levine MM, Sztein MB. 2007. Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909. Vaccine 25:1416-1425. https://doi.org/10.1016/j.vaccine.2006.10.040.
63. + T cell subset in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. J Immunol 173:5852-5862. https://doi.org/10.4049/jimmunol.173.9.5852.
64. Wahid R, Salerno-Gonçalves R, Tacket CO, Levine MM, Sztein MB. 2008. Generation of specific effector and memory T cells with gut- and secondary lymphoid tissue-homing potential by oral attenuated CVD 909 typhoid vaccine in humans. Mucosal Immunol 1:389-398. https://doi.org/10.1038/mi.2008.30.
65. Waddington CS, Darton TC, Jones C, Haworth K, Peters A, John T, Thompson BA, Kerridge SA, Kingsley RA, Zhou L, Holt KE, Yu LM, Lockhart S, Farrar JJ, Sztein MB, Dougan G, Angus B, Levine MM, Pollard AJ. 2014. An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solution. Clin Infect Dis 58:1230-1240. https://doi.org/10.1093/cid/ciu078.
66. + T cells play a dominant role in protection from typhoid fever in humans. J Transl Med 14:62. https://doi.org/10.1186/s12967-016-0819-7.
67. McArthur MA, Fresnay S, Magder LS, Darton TC, Jones C, Waddington CS, Blohmke CJ, Dougan G, Angus B, Levine MM, Pollard AJ, Sztein MB. 2015. Activation of Salmonella Typhi-specific regulatory T cells in typhoid disease in a wild-type S. Typhi challenge model. PLoS Pathog 11:e1004914. https://doi.org/10.1371/journal.ppat.1004914.
68. World Health Organization. 2002. Weekly epidemiological record. WHO, Geneva, Switzerland. http://www.who.int/immunization/wer7740 meningococcalOct02positionpaper.pdf.
69. Millar BC, Moore PJ, Moore JE. 30 December 2016. Meningococcal disease: has the battle been won? JRArmy Med Corps https://doi.org/10.1136/jramc-2016-000695.
70. MacLennan JM, Shackley F, Heath PT, Deeks JJ, Flamank C, Herbert M, Griffiths H, Hatzmann E, Goilav C, Moxon ER. 2000. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 283:2795-2801. https://doi.org/10.1001/jama.283.21.2795.
71. Snape MD, Pollard AJ. 2005. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 5:21-30. https://doi.org/10.1016/S1473-3099 (04) 01251-4.
72. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. 2004. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364:365-367. https://doi.org/10.1016/S0140-6736 (04) 16725-1.
73. Snape MD, Kelly DF, Salt P, Green S, Snowden C, Diggle L, Borkowski A, Yu LM, Moxon ER, Pollard AJ. 2006. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 43:1387-1394. https://doi.org/10.1086/508776.
74. Edwards EA, Devine LF, Sengbusch GH, Ward HW. 1977. Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence. Scand J Infect Dis 9:105-110.
75. Vygen S, Fischer A, Meurice L, Mounchetrou Njoya I, Gregoris M, Ndiaye B, Ghenassia A, Poujol I, Stahl JP, Antona D, Le Strat Y, Levy-Bruhl D, Rolland P. 2016. Waning immunity against mumps in vaccinated young adults, France 2013. Euro Surveill 21:30156. https://doi.org/10.2807/1560-7917. ES.2016.21.10.30156.
76. Rubin SA, Qi L, Audet SA, Sullivan B, Carbone KM, Bellini WJ, Rota PA, Sirota L, Beeler J. 2008. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wildtype mumps virus associated with a large outbreak. J Infect Dis 198:508-515. https://doi.org/10.1086/590115.
77. Broliden K, Abreu ER, Arneborn M, Bottiger M. 1998. Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two-dose immunization programme. Vaccine 16:323-327. https://doi.org/10.1016/S0264-410X (97) 88332-6.
78. Fiebelkorn AP, Coleman LA, Belongia EA, Freeman SK, York D, Bi D, Zhang C, Ngo L, Rubin S. 2014. Mumps antibody response in young adults after a third dose of measles-mumps-rubella vaccine. Open Forum Infect Dis 1: ofu094. https://doi.org/10.1093/ofid/ofu094.
79. Kontio M, Jokinen S, Paunio M, Peltola H, Davidkin I. 2012. Waning antibody levels and avidity: implications for MMR vaccine-induced protection. J Infect Dis 206:1542-1548. https://doi.org/10.1093/infdis/jis568.
80. Latner DR, McGrew M, Williams N, Lowe L, Werman R, Warnock E, Gallagher K, Doyle P, Smole S, Lett S, Cocoros N, DeMaria A, Konomi R, Brown CJ, Rota PA, Bellini WJ, Hickman CJ. 2011. Enzyme-linked immunospot assay detection of mumps-specific antibody-secreting B cells as an alternative method of laboratory diagnosis. Clin Vaccine Immunol 18:35-42. https://doi.org/10.1128/CVI.00284-10.
81. DiLillo DJ, Ravetch JV. 2015. Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell 161:1035-1045. https://doi.org/10.1016/j.cell.2015.04.016.
82. Wang TT, Maamary J, Tan GS, Bournazos S, Davis CW, Krammer F, Schlesinger SJ, Palese P, Ahmed R, Ravetch JV. 2015. Anti-HA glycoforms drive B cell affinity selection and determine influenza vaccine efficacy. Cell 162:160-169. https://doi.org/10.1016/j.cell.2015.06.026.
83. Miller JE, Hammond GC, Strunk T, Moore HC, Leonard H, Carter KW, Bhutta Z, Stanley F, de Klerk N, Burgner DP. 2016. Association of gestational age and growth measures at birth with infection-related admissions to hospital throughout childhood: a population-based, datalinkage study from Western Australia. Lancet Infect Dis 16:952-961. https://doi.org/10.1016/S1473-3099 (16) 00150-X.
84. Pettengill MA, van Haren SD, Levy O. 2014. Soluble mediators regulating immunity in early life. Front Immunol 5:457. https://doi.org/10.3389/fimmu.2014.00457.
85. van Haren SD, Dowling DJ, Foppen W, Christensen D, Andersen P, Reed SG, Hershberg RM, Baden LR, Levy O. 2016. Age-specific adjuvant synergy: dual TLR7/8 and Mincle activation of human newborn dendritic cells enables Th1 polarization. J Immunol 197:4413-4424. https://doi.org/10.4049/jimmunol.1600282.
86. Philbin VJ, Dowling DJ, Gallington LC, Cortés G, Tan Z, Suter EE, Chi KW, Shuckett A, Stoler-Barak L, Tomai M, Miller RL, Mansfield K, Levy O. 2012. Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. J Allergy Clin Immunol 130:195-204. https://doi.org/10.1016/j.jaci.2012.02.042.
87. Dowling DJ, van Haren SD, Scheid A, Bergelson I, Kim D, Mancuso CJ, Foppen W, Ozonoff A, Fresh L, Theriot TB, Lackner AA, Fichorova RN, Smirnov D, Vasilakos JP, Beaurline JM, Tomai MA, Midkiff CC, Alvarez X, Blanchard JL, Gilbert MH, Aye PP, Levy O. 2017.
88. Martins KA, Cooper CL, Stronsky SM, Norris SL, Kwilas SA, Steffens JT, Benko JG, van Tongeren SA, Bavari S. 2016. Adjuvant-enhanced CD4 T cell responses are critical to durable vaccine immunity. EBioMedicine 3:67-78. https://doi.org/10.1016/j.ebiom.2015.11.041.
89. Wilk MM, Misiak A, McManus RM, Allen AC, Lynch MA, Mills KHG. 22 May 2017. Lung CD4 tissue-resident memory T cells mediate adaptive immunity induced by previous infection of mice with Bordetella pertussis. J Immunol https://doi.org/10.4049/jimmunol.1602051.